More than 100 organizations use Vault CTMS to unify data and
processes for faster, more efficient trials
BARCELONA, Spain, May 13, 2021 /PRNewswire/ -- As the need for
greater efficiency in studies grows, more than 100 companies are
streamlining trial management and monitoring with Veeva Vault CTMS.
Fast-growing companies and global organizations are modernizing
their clinical systems landscape and investing in unified
applications from Veeva Systems (NYSE: VEEV) to increase visibility
across trials and accelerate study execution.
"We needed a scalable clinical system that can grow with us
while supporting multiple operating models and complex study
designs," said Charles Johnson,
director eClinical operations at CSL Behring. "Veeva Vault CTMS
delivers the flexibility to meet our unique business requirements
and seamlessly share information with Veeva Vault eTMF,
significantly reducing data entry and streamlining document
filing."
Usability issues with legacy systems have driven the industry to
rely on manual and paper-based processes that slow down studies.
With Vault CTMS, customers are simplifying costly and
time-consuming processes like site monitoring by enabling CRAs to
auto-generate trip reports and file them seamlessly within Vault
eTMF. The increased productivity allows users to move faster while
ensuring compliance.
"Our clinical research associates used to spend more than 160
hours per study preparing trip reports in
our homegrown CTMS application," said Hunter Walker, CTO at Atlantic Research Group.
"Veeva Vault CTMS significantly decreased monitoring
time, lowered trial costs, and simplified execution, enabling us to
deliver greater efficiencies to our clients."
"There is incredible momentum in the adoption of Veeva Vault
CTMS because of its ability to scale with growing companies and
improve trial oversight for sponsors and CROs," said Henry Galio, senior director, Veeva Vault CTMS.
"We are laser-focused on helping customers of all sizes speed
execution and lower costs in clinical research."
Vault CTMS is part of the Veeva Vault Clinical Operations
Suite, enabling companies to share information and documents across
CTMS, eTMF, study start-up, and payments for better collaboration
and increased efficiency throughout the study lifecycle.
Learn more about Vault CTMS at the upcoming Veeva R&D
and Quality Summit Connect Europe, 20 May
2021. The online event is open to life sciences industry
professionals. Register and stay up to date on program details
at veeva.com/Summit.
Additional Information
For more on Veeva Vault CTMS,
visit: veeva.com/CTMS
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer
success, Veeva serves more than 975 customers, ranging
from the world's largest pharmaceutical companies to emerging
biotechs. As a Public Benefit Corporation, Veeva is committed to
balancing the interests of all stakeholders, including
customers, employees, shareholders, and the industries
it serves. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains
forward-looking statements, including the market demand for and
acceptance of Veeva's products and services, the results from use
of Veeva's products and services, and general business conditions
(including the on-going impact of COVID-19), particularly within
the life sciences industry. Any forward-looking statements
contained in this press release are based upon Veeva's historical
performance and its current plans, estimates, and expectations, and
are not a representation that such plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Veeva's expectations as of the date of this press
announcement. Subsequent events may cause these expectations to
change, and Veeva disclaims any obligation to update the
forward-looking statements in the future. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially. Additional
risks and uncertainties that could affect Veeva's financial results
are included under the captions, "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations," in the company's filing on Form 10-K for the period
ended January 31, 2021. This is available on the
company's website at veeva.com under the Investors
section and on the SEC's website at sec.gov. Further
information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from
time to time.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg